Trajenta Is Often A Dangerous Drug, Despite Findings In Mice

| June 21, 2017

The headline “Diabetes drug protects against heart disease” recently caught my attention, so I read on. It appears that Trajenta was found to prevent early markers of heart disease in mice. The trouble is, this drug is already known to help cause heart problems in humans, along with other dangerous side effects.

Researchers at the University of Missouri School of Medicine fed mice a “Western diet” – high in sugar and fat – and half of them had a dose of Trajenta added to their food. The mice that didn’t get the drug showed several signs of impending heart problems, including stiffening of the heart muscle and a heartbeat abnormality called diastolic dysfunction. The Trajenta-treated mice had less of these heart disease markers.1

Reading the study, it sounds like Trajenta is a wonder drug for people whose heart disease risk is raised because of type 2 diabetes. But then it would sound that way – because this study was fully funded by the drug’s manufacturer, Boerhinger Ingelheim, who also had a hand in writing the published paper!

Trajenta (linagliptin) belongs to the DPP-4 inhibitor family of drugs, which are known to raise the risk of heart failure in humans, as I reported here. Like its close relative Januvia (see here), it also increases the risk of acute pancreatitis, a potentially fatal condition, according to the manufacturer’s own pre-marketing trials. In the US, several Trajenta lawsuits are pending, and a possible link with pancreatic cancer has also emerged.

In addition, Trajenta side effects listed by as “more common” include coma (yes, really!), seizures, severe joint or back pain, nightmares, dizziness, confusion, depression and slurred speech. And that’s just for starters. Despite the findings from the latest mouse study, Trajenta remains a dangerous, unpleasant drug that is best avoided.

Wishing you the best of health,

Martin Hum
PhD DHD Nutritionist
for Real Diabetes Truth

Did you find this information useful?

If you enjoyed this content or found it useful and educational, please share this article with your friends and family.

Bear in mind we are not addressing anyone’s personal situation and you should rely on this for informational purposes only. Please consult with your own physician before acting on any recommendations contained herein.

1. Aroor AR, Habibi J, Kandikattu HK et al. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice. Cardiovasc Diabetol. 2017; 16(1):61. 

Print Friendly

Tags: , ,

Category: Diabetes Drugs

Comments are closed.